The present disclosure is directed to adapters for mixing vials of drug products, and more specifically to multi-vial adapters for reconstituting lyophilized drug products and/or diluting concentrated drug products. It is an object to address one or more of drawbacks in connection with the drug preparation process, for example, by simplifying the procedure where multiple vials are required to be diluted or reconstituted in a serial manner. As such, the multi-vial adapters described herein simplify the complexity of preparing and handling multiple vials of drug product, which significantly reduces preparation time, addresses dosing-related challenges like weight-based preparation, reduces drug waste issues, and reduces risks associated sterility and contamination, among other benefits.
The present disclosure is directed to adapters for mixing vials of drug products, and more specifically to multi-vial adapters for reconstituting lyophilized drug products and/or diluting concentrated drug products. It is an object to address one or more of drawbacks in connection with the drug preparation process, for example, by simplifying the procedure where multiple vials are required to be diluted or reconstituted in a serial manner. As such, the multi-vial adapters described herein simplify the complexity of preparing and handling multiple vials of drug product, which significantly reduces preparation time, addresses dosing-related challenges like weight-based preparation, reduces drug waste issues, and reduces risks associated sterility and contamination, among other benefits.
Disclosed is a fluid guide system (FGS) usable for drug (D) handling, comprising:
At least one fluid port (FP) configured to dispense a fluid from the fluid guide system (FGS), and
At least two drug port (DP), each being configured to receive a fluid comprising at least one drug (D) from at least one drug container (DC),
wherein each of the at least two drug ports (DC) is coupleable or coupled to at least one drug container (DC) such that a plurality of drug containers (DC) can be or is jointly mechanically coupled to the fluid guide system (FGS).
Disclosed is a fluid guide system (FGS) usable for drug (D) handling, comprising: - At least one fluid port (FP) configured to dispense a fluid from the fluid guide system (FGS), and - At least two drug port (DP), each being configured to receive a fluid comprising at least one drug (D) from at least one drug container (DC), wherein each of the at least two drug ports (DC) is coupleable or coupled to at least one drug container (DC) such that a plurality of drug containers (DC) can be or is jointly mechanically coupled to the fluid guide system (FGS).
The application relates to a lock ring for a medicament delivery device. The lock ring comprises a hollow main body formed from a plurality of circumferentially extending portions. Each portion is defined between tool split lines defining circumferential ends of the portions. Each circumferential end of a portion is connected to an adjacent portion along a tool split line. The main body comprises a plurality of bearing elements configured to contact a body of a medicament delivery device. Each of the plurality of bearing elements is configured to form a low friction rotation interface. At least one of the plurality of bearing elements is formed proximate to one of the circumferential ends of a portion of the main body.
A medicament delivery device for injecting medicament comprises a body 301 comprising a distal end, a proximal end, and a longitudinal axis extending from the distal end to the proximal end. A plunger rod is configured to be movable in a distal direction of the body, the plunger rod comprising a plunger rod engagement surface. A locking element is moveable from a first position to a second position. In the first position, movement of the plunger rod in the distal direction is prevented. In the second position, movement of the plunger rod in the distal direction is permitted. A release member is configured to be moveable from a blocking position in which the release member is configured to prevent the locking element from moving to a release position in which the release member is configured to permit the locking element to.
A medicament delivery device for injecting medicament which has a body having a proximal end and a distal end, a needle for injecting medicament and an actuation member which is movable relative to the body. The actuation member is movable from a first position to a second position and movable from the second position to a dispensing position for dispensing medicament from the needle. The second position is proximal of the first position. The medicament delivery device further has a cap which is removably attached to the medicament delivery device. The cap has a portion configured to prevent movement of the actuation member from the first position to the second position when the cap is attached to the medicament delivery device.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A medicament delivery device is described. The device includes a body comprising a proximal end and a distal end; a needle for injecting medicament; an actuation member moveable relative to the body for actuating the device; a lock ring configured to rotate relative to the body between a first position in which the actuation member is not permitted to move relative to the body, and a second position in which the actuation member is permitted to move relative to the body; and a cap arrangeable in a capped position in which the cap abuts with and conceals the distal end of the body to conceal the needle; wherein when the cap is in the capped position the lock ring is in a first state in which the lock ring is in the first position and is not permitted to rotate towards the second position; and wherein moving the cap in a distal direction away from the distal end of the body along the longitudinal axis away from the capped position causes the lock ring to be in a second state in which the lock ring is permitted to rotate from the first position towards the second position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials
According to a first aspect of this disclosure, there is described an injection device includes: a body; a needle shroud retractable into the body including a shroud pin; a collar rotatable with respect to the body and including a cam track engageable with the shroud pin. The cam track includes: a first portion configured to, during retraction of the needle shroud into the body, guide the shroud pin from an initial position to a hold position and cause the collar to rotate relative to the body; a second portion configured to, during extension of the needle shroud from the body subsequent to the retraction, guide the shroud pin from the hold position to a final position and cause the collar to further rotate relative to the body; and a non-return surface configured to, subsequent to the extension, prevent further retraction of the needle shroud into the body.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
In one aspect the present disclosure relates to a medicament container (10) for a lyophilizable and reconstitutable pharmaceutical product (6, 7), the medicament container (10) comprising: - a flexible bag (11) defining a chamber (12), - the chamber (12) comprising a chamber cavity (13) configured to hold the pharmaceutical product (6, 7), wherein the chamber cavity (13) is confined at least in sections by a chamber wall (18), - wherein the chamber wall (18) comprises a membrane portion (34), which is semipermeable and allows permeation of vapor (9) from the chamber cavity (13) through the membrane portion (34) to an exterior (4) of the chamber (12), and - an outer wrapping (50) entirely enclosing the flexible bag (11).
In one aspect the present disclosure relates to a medicament container (10) for a lyophilizable and reconstitutable pharmaceutical product (6, 7), the medicament container (10) comprising: - a first chamber (12) comprising a first chamber cavity (13) configured to hold the pharmaceutical product (6, 7), wherein the first chamber cavity (13) is confined at least in sections by a first chamber wall (18), - a second chamber (14) connected or fixed to the first chamber (12) and comprising a second chamber cavity (15) configured to hold a reconstituting liquid (8), wherein the second chamber cavity (15) is separated from the first chamber cavity (13), - a liquid-tight barrier (16) between the first chamber cavity (13) and the second chamber cavity (15) and - wherein the first chamber wall (18) comprises a membrane portion (34), which is semipermeable and allows permeation of vapor (9) from the first chamber cavity (13) through the membrane portion (34) to an exterior (4) of the first chamber (12).
Some injection devices include an injection device body, a needle shroud retractable into the injection device body, a control spring coupled to the needle shroud and biased to cause the needle shroud to be at least partially extended from the injection device body in an initial position, and a hold detent mechanism coupled to at least the needle shroud. The hold detent mechanism is configured to (i) activate, when the needle shroud is retracted from the initial position into the injection device body to a hold position, to create a hold detent force, and (ii) deactivate, when the needle shroud is extracted from the hold position subsequent to the retraction, to release the hold detent force and enable the needle shroud to extend from the injection device body to substantially the initial position.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
According to a first aspect of this disclosure, there is described an injection device includes: a body; a needle shroud retractable into the body including a shroud pin; a collar rotatable with respect to the body and including a cam track engageable with the shroud pin. The cam track includes: a first portion configured to, during retraction of the needle shroud into the body, guide the shroud pin from an initial position to a hold position and cause the collar to rotate relative to the body; a second portion configured to, during extension of the needle shroud from the body subsequent to the retraction, guide the shroud pin from the hold position to a final position and cause the collar to further rotate relative to the body; and a non-return surface configured to, subsequent to the extension, prevent further retraction of the needle shroud into the body.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
16.
COLLAR HOLD DETENT MECHANISM AND LOCK FOR INJECTION DEVICES
This application relates to an injector device for delivery of a medicament, particularly to an auto-injector device. According to a first aspect of this disclosure, there is described an injection device comprising: an injection device body; a needle shroud retractable into the injection device body comprising a shroud pin; a control spring coupled to the needle shroud and biased to cause the needle shroud to be at least partially extended from the injection device body in an initial position; and a collar rotatable with respect to the injection device body and comprising a cam track engageable with the shroud pin; a hold detent mechanism coupled to the cam track of the collar, wherein the hold detent mechanism is configured to: activate, when the needle shroud is retracted from a first position on the cam track into the injection device body to a hold position on the cam track, by engaging the shroud pin thereby creating a hold detent force opposite a control spring force caused by compression of the control spring during said retraction of needle shroud to said hold position; and deactivate, when the needle shroud is extracted from the hold position on the cam track subsequent to the retraction towards a second position on the cam track, by disengaging the shroud pin thereby releasing the hold detent force and enable the needle shroud to extend from the injection device body to the second position on the cam track; and wherein the hold detent mechanism further comprises a non-return surface configured to, subsequent to the extension of the needle shroud, prevent further retraction of the needle shroud into the injection device body along the cam track towards the hold position.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
This application relates to an injector device for delivery of a medicament, particularly to an auto-injector device. According to a first aspect of this specification, there is described an injection device comprising: an injection device body; a plunger comprising one or more plunger recesses; biasing means for applying a biasing force to bias the plunger in a distal direction of the injection device; a casing at least partially enclosing the plunger, the casing comprising one or more toothed beams each comprising a tooth engageable with a corresponding plunger recess of the one or more plunger recesses; and a rotatable collar at least partially enclosing the casing and comprising one or more collar recesses on an inner surface of the rotatable collar; and wherein: each of the one or more plunger recesses is shaped to urge a tooth of the corresponding toothed beam outwards when the biasing force is applied to the plunger in a pre-use configuration; and the one or more collar recesses are shaped to cooperate with a tooth of a corresponding toothed beam to apply a torque to the rotatable collar when the corresponding toothed beam is urged outwards in the pre-use configuration.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
An injection device includes a housing, a needle shroud movable within the housing between an extended position and a retracted position, and a needle shroud latch configured to hold the needle shroud in its retracted position. The needle shroud latch includes a button arranged at the housing such that a user can actuate the button by applying an actuation force to the button to hold the needle shroud in its retracted position.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
19.
POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE TRANSFERRIN RECEPTOR 1
The present invention relates to polypeptides that are capable of binding to a specific pH-dependent epitope on the (human) transferrin receptor 1 (TfR1). In particular, the present invention relates to novel and improved immunoglobulin single variable domains (ISVDs), such as heavy-chain single variable domains, which are capable of binding to a specific epitope on TfR1. The invention further relates to polypeptides, nucleic acids, vectors, host cells, conjugates, or pharmaceutical compositions that comprise at least one of these ISVDs binding to a specific epitope on TfR1. The present invention further relates to methods for producing such ISVDs as well as to uses of such polypeptides for diverse therapeutic, diagnostic and/or medical imaging applications, including but not limited to the delivery of therapeutic, diagnostic and/or medical imaging agents across the blood-brain barrier (BBB), and/or into a cell of a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61P 25/00 - Drugs for disorders of the nervous system
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes: a first support configured to be fixedly coupled to a main body of a medicament delivery device, wherein the first support comprises a first attraction component; and a second support moveable relative to the first support between an initial position and a hold position and configured to be fixedly coupled to a needle cover of the medicament delivery device, wherein the second support includes a second attraction component, and wherein at least one of the first attraction component and the second attraction component is a magnet, and the other of the first attraction component and the second attraction component is a magnet or a ferromagnetic material; and wherein movement of the second support towards the hold position moves the second attraction component towards the first attraction component.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
An injection device comprises: an injection device body; a needle shroud comprising a shroud pin; and a collar rotatable with respect to the injection device body and comprising a cam track. During retraction of the needle shroud, a first portion of the cam track guides the shroud pin to a hold position and cause the collar to rotate relative to the injection device body from a first position to a second position. During a subsequent extension of the needle shroud, a second portion of the cam track guides the shroud pin from the hold position to a final position and causes the collar to further rotate relative to the injection device body from the second position to a third position, the second portion comprising a blocking portion configured to prevent extension of the needle shroud from the injection device body when the collar is held in the second position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A damping device for a medicament delivery device, comprising: a generally cylindrical first collar; a housing comprising a generally annular cavity configured to receive at least a portion of the first collar; wherein the first collar is configured to be rotatable relative to the housing about a central longitudinal axis of the damping device, and wherein the cavity is configured to contain a fluid for impeding rotational movement of the first collar relative to the housing; and a sealing arrangement configured to fluidly seal an interface between the housing and the first collar.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07F 9/6506 - Five-membered rings having the nitrogen atoms in positions 1 and 3
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials
27.
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION
The USA, as Represented by the Secretary, Department of Health and Human Service (USA)
Inventor
Wadsworth, Samuel
Scaria, Abraham
Chan, Chi-Chao
Abstract
Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A medicament delivery device includes a needle, a needle cover, and a body. The needle cover is axially movable relative to the body between an initial position in which the needle cover covers the needle and an activated position for dispensing medicament from the device. The medicament delivery device includes a carrier configured to support a syringe. The carrier is disposed within the needle cover and includes one or more resilient members. The needle cover includes one or more first slots and one or more second slots. The one or more resilient members are each configured to (i) engage with a respective one of the one or more first slots when the needle cover is in the initial position, and to (ii) enter a respective one of the one or more second slots after a proximal movement of the needle cover from the initial position to an intermediate position.
A medicament delivery device includes a needle disposed at a distal end of the medicament delivery device, a body for a syringe, and a needle cover axially movable relative to the body between an extended position in which the needle cover covers the needle and a retracted position for dispensing medicament from the medicament delivery device. The needle protruding from the distal end of the needle cover when the needle cover is in the retracted position. The medicament delivery device includes an actuation member configured to be movable from an initial position to an engaged position such that when the actuation member is in its initial position, the needle cover can be axially moved between its retracted position and its extended position, and when the actuation member is in its engaged position, the actuation member engages with the needle cover to hold the needle cover in its retracted position..
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A medicament delivery device includes a needle disposed at a distal end of the medicament delivery device. The medicament delivery device includes a body for a syringe and a needle cover axially movable relative to the body between an extended position in which the needle cover covers the needle and a retracted position in which the needle protrudes from the distal end of the needle cover. The medicament delivery device includes a plunger axially movable relative to the body to dispense medicament from the medicament delivery device. The medicament delivery device includes a needle cover biasing mechanism configured to bias the needle cover distally from the retracted position to the extended position. The medicament delivery device includes a locking mechanism configured to be moved by the plunger from an initial configuration to an engaged configuration to prevent a distal movement of the needle cover biasing mechanism.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A medicament delivery device for reducing a force required to activate the device includes a needle disposed at a distal end of the device, a needle cover, and a body. The needle cover is axially movable relative to the body between an initial position in which the needle cover covers the needle and an activated position for dispensing medicament. The needle protrudes from the distal end of the needle cover when the needle cover is in the activated position. The medicament delivery device includes a carrier configured to support a syringe. The carrier is disposed within the needle cover and includes a deformable element configured to change from a first configuration in which the deformable element is engaged with the needle cover to a second configuration in which the deformable element is not engaged with the needle cover.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Provided are lipid nanoparticles, compositions, and methods of making and using the same. The lipid nanoparticles contain ionizable lipids, structural lipids, PEG lipids and specific amounts of helper lipids. The lipid nanoparticles may further contain a cell targeting group coupled to a PEG lipid. The lipid nanoparticles may carry a cargo, e g., a mRNA. The lipid nanoparticles may be used for transfection of cells, e.g., immune cells or hematopoietic stem cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
There is provided a medicament delivery device comprising: a main body arranged to receive a medicament cartridge; a needle for delivery of medicament from the medicament cartridge; a needle cover moveable between an initial position, in which the needle cover covers the needle, and an activated position for dispensing medicament from the medicament delivery device, wherein in the activated position the needle protrudes from a distal end of the needle cover; an outer frame, moveable relative to the main body between an extended position in which the outer frame extends past a distal end of the needle, and a retracted position in which the outer frame is moved towards the main body; an attachment element comprising an adhesive region for attaching the medicament delivery device to a surface when the needle cover is in the activated position, the attachment element comprising a protective barrier covering the adhesive region.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A medicament delivery device includes a needle disposed at a distal end of the medicament delivery device, a body for a syringe, and a needle cover axially movable relative to the body between an extended position in which the needle cover covers the needle and a retracted position for dispensing medicament from the medicament delivery device. The needle protruding from the distal end of the needle cover when the needle cover is in the retracted position. The medicament delivery device includes an actuation member configured to be movable from an initial position to an engaged position such that when the actuation member is in its initial position, the needle cover can be axially moved between its retracted position and its extended position, and when the actuation member is in its engaged position, the actuation member engages with the needle cover to hold the needle cover in its retracted position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A medicament delivery device has a needle, a body and a needle cover which is axially movable from an initial position to a holding position to a locked position in which the needle cover covers the distal end of the needle. The device has a biasing member configured to bias the needle cover distally, and a guide member configured to rotate relative to the needle cover. One of the guide member and the needle cover has a pin and the other of the guide member and the needle cover has a guide path for guiding the pin. The guide path has a first ramp, a second ramp and a locking abutment surface. When the needle cover is in the locked position then the locking abutment surface is configured to engage the pin to prevent the needle cover from moving proximally away from the locked position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A medicament delivery device comprises: a needle for injecting a medicament; a body; a needle cover axially movable relative to the body between an extended position and a retracted position; a needle cover biasing member configured to bias the needle cover distally; a medicament delivery mechanism; and a latch movable by the needle cover between an engaged configuration, in which the latch prevents delivery of the medicament, and a disengaged configuration, in which the latch allows delivery of the medicament, wherein the needle cover is configured such that: proximal movement of the needle cover from the extended position towards the retracted position moves the latch from the engaged configuration to the disengaged configuration; and distal movement of the needle cover from the retracted position towards the extended position moves the latch from the disengaged configuration to the engaged configuration.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Provided are methods for assessing aberrant glycosphingolipid processing, and methods for determining the severity and/or progression of diseases associated therewith. Also provided are methods for assessing the likely therapeutic response of a subject to treatment with agents that can modulate glycosphingolipid processing, as well as therapeutic methods which benefit from assessing the patient in accordance with the disclosure. The methods of the disclosure employ an agent (e.g., conduritol-β epoxide) which can challenge the glycosphingolipid pathway in a cell, followed by monitoring the recovery of the cell, e.g., monitoring the restoration of glycosphingolipid flux in the cell.
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
C12N 9/96 - Stabilising an enzyme by forming an adduct or a compositionForming enzyme conjugates
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
A medicament delivery device includes: a body; a needle cover axially movable between an extended position and a retracted position; a medicament delivery mechanism including a plunger and a drive member configured to move the plunger to dispense a medicament; an actuation member configured to be actuated relative to the body; and a ratchet mechanism coupled to the medicament delivery mechanism and sequentially movable between a first configuration, second configuration and third configuration, wherein the actuation member and ratchet mechanism are arranged such that: a first actuation of the actuation member moves the ratchet mechanism from the first configuration to the second configuration to cause a first dose of the medicament to be dispensed, and a second actuation of the actuation member, subsequent to the first actuation, moves the ratchet mechanism from the second configuration to the third configuration to cause a second dose of the medicament to be dispensed.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
42.
CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
The invention provides a crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, methods of inhibiting tropomyosin-related kinase and/or c-FMS, and methods of treating medical diseases and conditions, such as pain.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A fluid transfer device comprises a body comprising a first connecting portion comprising a first fluid channel to fluidically communicate with an interior of a diluent container, a second connecting portion comprising a second fluid channel to fluidically communicate with an interior of a medicament container, a third connecting portion comprising a third fluid channel to fluidically communicate with an interior of a pooling container, and a fourth fluid channel to fluidically communicate with a pump device. A movable part is engaged with and movable relative to the body to transfer the fluid transfer device into one of a first configuration, a second configuration and a third configuration. When in the first configuration, the second fluid channel is fluidically coupled to the third fluid channel, and when in the second configuration, the first fluid channel is fluidically connectable to the third fluid channel.
A medicament delivery device for injecting a medicament is described. The medicament delivery device comprises a housing having a proximal end and a distal end, the housing being configured to receive a medicament container. A plunger is moveable in a longitudinal direction within the housing for dispensing medicament from the medicament container when the medicament container is received within the housing. A plunger drive magnet is operatively coupled to the housing, and the plunger drive magnet is configured to provide a magnetic field. A component is configured to magnetically interact with the magnetic field of the plunger drive magnet so as to cause a force to be exerted on the plunger for causing the plunger to move in the longitudinal direction.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
46.
Hold assistance device for use with a medicament delivery device
A hold assistance device for use with a medicament delivery device including a moveable needle cover. The hold assistance device comprises a housing coupled to a medicament delivery device, the housing comprising a proximal end and a distal end defining an axis between the proximal and distal ends; a holding element coupled to the housing and moveable relative to the housing in a direction substantially normal to the axis of the housing between a disengaged position and an engaged position; wherein the holding element is disposed outwardly from the axis in the disengaged position and is disposed inwardly towards the axis in the engaged position configured in the engaged position such that the holding element can engage with an aperture or recess in a needle cover of a medicament delivery device when the hold assistance device is coupled thereto, to resist movement of the needle cover relative to the housing.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
47.
Hold assistance device for use with a medicament delivery device
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes a body that includes: a receiving volume for receiving a medicament delivery device; a proximal portion comprising a proximal end of the body; a distal portion comprising a distal end of the body, the proximal and distal ends defining an axial direction; and a connecting portion arranged between the proximal and distal portions, wherein the connecting portion is configured to flex into the receiving volume in a direction generally normal to the axial direction, causing the proximal portion to move axially relative to the distal portion.
A medicament delivery device comprising a body, a needle, and an actuation member movable proximally from an initial position to a protruded position, and distally from the protruded position to an actuation position. The device has a transfer member which is movable proximally between an extended and a retracted position. In the extended position the distal end of the transfer member protrudes from the body. One of the actuation member and the transfer member has a drive slot and the other of the actuation member and the transfer member comprises a protrusion located in the drive slot. The drive slot has a circumferentially-extending portion having an abutment surface. The protrusion engages the abutment surface to move the actuation member from the initial position to the protruded position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
49.
Multivariate Spectral Analysis and Monitoring for Biomanufacturing
The disclosure features methods that include obtaining a vibrational spectrum of a solution in a biological manufacturing system, analyzing the vibrational spectrum using a first chemometrics model to determine a value of a first quality attribute associated with the solution, analyzing the vibrational spectrum using a second chemometrics model to determine a value of a second quality attribute associated with the solution, and adjusting at least one parameter of a purification unit of the biological manufacturing system based on at least one of the values of the first and second quality attributes.
G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
C07K 1/16 - ExtractionSeparationPurification by chromatography
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
Provided herein are artificial microRNA (miRNA) molecules for treating synucleinopathies. In some embodiments, the miRNA molecules target expression of SNCA protein. Further provided herein are expression constructs, vectors (e.g., rAAV), cells, viral particles, and pharmaceutical compositions containing the artificial miRNA molecules. Yet further provided herein are methods and kits related to the use of the miRNA molecules, for example, to treat synucleinopathies including Parkinson's Disease, Multiple System Atrophy, or Dementia with Lewy Bodies.
Provided herein are artificial miRNA molecules for treating Huntington's Disease (HD). In some embodiments, the artificial miRNA molecules target expression of HTT protein. Further provided herein are expression constructs, vectors (e.g., rAAV), cells, viral particles, and pharmaceutical compositions capable of expressing the artificial miRNA molecules. Yet further provided herein are methods and kits related to the use of the artificial miRNA molecules, for example, to treat HD.
The disclosure relates to methods of delivering a gene therapy agent to a subject, treating an individual in need of a gene therapy agent, increasing expression of a gene therapy agent, reducing an immune response to a gene therapy agent, and preventing immune-related adverse events in a subject by administering a gene therapy agent and an IL-2 conjugate to the subject. The IL-2 conjugate has at least one amino acid residue replaced by an unnatural amino acid linked to a conjugating moiety. The disclosure further relates to methods of selecting a subject for treatment with a gene therapy agent and an IL-2 conjugate.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Provided herein are methods to treat various neurodegenerative disorders comprising delivering a viral particles to the whole brain, including both superficial and deep structures. In some aspects, the viral particles are administered at low dose levels to the CSF, in conjunction with microbubbles followed by application of focused ultrasound (FUS) to a region of interest of the brain, thereby causing entry of the viral particles to the brain.
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes: a housing configured to be fixedly coupled to a medicament delivery device, the housing comprising: a proximal end and a distal end defining an axial direction, and an inclined surface angled relative to the axial direction; a blocking element moveable along the inclined surface; and an actuation element moveable relative to the housing and arrangeable in an activated position in which the actuation element applies an activation force to the blocking element in a direction towards the distal end, such that movement of the actuation element into the activated position causes the blocking element to move against the inclined surface towards the distal end and to exert a clamping force generally normal to the axial direction.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.
A vial adapter comprises an adapter body comprising a top wall and a sidewall projecting from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall. The receptacle is configured to receive at least a portion of a barrel head of an injection vial. A movable part comprises a base part and a spike fixed to the base part. The spike extends through the top wall in a distal direction into the receptacle. An actuating member is mechanically coupled to the movable part, and is movable relative to the adapter body from a start position to an end position along a first direction to induce a distally directed displacement of the movable part relative to the adapter body. The mechanical coupling between the movable part and the actuating member is releasable when the actuating member is in the end position.
A medicament delivery device includes a first component, a second component configured to be movable with respect to the first component, and a temperature-dependent interconnect configured to resist movement of the first component relative to the second component. The temperature-dependent interconnect includes an engagement member and a temperature-dependent material configured to engage each other. The temperature-dependent material has a temperature-dependent material characteristic such that the temperature-dependent material has (i) a first material characteristic at a first temperature of the temperature-dependent material to resist movement of the first component with respect to the second component, and (ii) a second material characteristic at a second temperature of the temperature-dependent material to allow movement of the first component with respect to the second component.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
68.
Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
A vial adapter for connecting to an injection vial comprises a barrel and a barrel head with an outlet that is sealed by a pierceable stopper. The vial adapter comprises an adapter body comprising a top wall and a sidewall. The sidewall projects from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall The receptacle is configured to receive at least a portion of the barrel head. A movable part comprises a base part and an elongated fluid channel extending through the top wall along the longitudinal direction. The elongated fluid channel comprises a proximal channel section merging into a mechanical connector, and a distal channel section with a channel aperture. The movable part is adjustably movable relative to the adapter body along the longitudinal direction to align the channel aperture with an inside surface of the pierceable stopper.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Chemicals, namely, hyaluronic acid, hyaluronans and hylan polymers, and derivatives thereof, for use in the manufacture of cosmetics, medicated and non-medicated personal care products; chemicals, namely, hyaluronic acid, hyaluronans and hylan polymers, and derivatives thereof, in combination with polysaccharides for use in the manufacture of cosmetics, medicated and non-medicated care products; chemicals for use in the manufacture of cosmetic, personal care and pharmaceutical products; chemical additives for use in the manufacture of pharmaceuticals
(2) Pharmaceuticals for use in surgery namely hyaluronic acid hyaluronans and derivatives thereof alone or in combination with other polysaccharides
(3) Medical Devices namely self contained syringes and ampules for dispensing prepackaged hyaluronic acid hyaluronans and hylan and derivatives thereof alone or in combination with other polysaccharides for topical use in surgery
A medicament delivery device includes an actuator including an actuation member configured to be movable by a user to an actuation position to cause a dose of medicament to be dispensed from the medicament delivery device. The actuator is configured to be movable from a deactivated position in which a user is prevented from moving the actuation member to the actuation position to an activated position in which the actuation member is released for movement by a user to the actuation position. The device includes a temperature-dependent actuator configured to move the actuator from the deactivated position to the activated position in response to a change in temperature of the temperature-dependent actuator.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemicals, namely, hyaluronic acid, hyaluronans and hylan polymers, and derivatives thereof, for use in the manufacture of cosmetics, medicated and non-medicated personal care products; chemicals, namely, hyaluronic acid, hyaluronans and hylan polymers, and derivatives thereof, in combination with polysaccharides for use in the manufacture of cosmetics, medicated and non-medicated care products; chemicals for use in the manufacture of cosmetic, personal care and pharmaceutical products; chemical additives for use in the manufacture of pharmaceuticals. Pharmaceuticals for use in surgery, namely, hyaluronic acid hyaluronans and derivatives thereof alone or in combination with other polysaccharides. Medical devices, namely, self contained syringes and ampules for dispensing prepackaged hyaluronic acid hyaluronans and hylan and derivatives thereof alone or in combination with other polysaccharides for topical use in surgery.
A medicament delivery device includes a needle being axially moveable from a retracted position to an exposed position. The device includes an actuation member configured to be movable to an actuation position to cause the needle to move from the retracted position to the exposed position. The device includes a locking member for preventing the movement of the actuation member to the actuation position, and a locking release member being axially moveable towards a proximal end of the medicament delivery device from a first position, in which the locking member is prevented from moving to a release position in which the actuation member is released for the movement of the actuation member to the actuation position, to a second position, in which the locking member is free to move to the release position in which the actuation member is released for the movement of the actuation member to the actuation position.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The present disclosure relates to a compound of formula (1) as an anhydrate which is in a crystalline Form 1, characterized by having a powder-X-ray diffractogram displaying a peak expressed as degree 2-Theta angles at about 8.3 and a solid form thereof. The present disclosure also relates to processes for its preparation, as well as a medicament and a pharmaceutical composition comprising it. The present disclosure further concerns the anhydrate crystalline Form 1 of compound of formula (1) for use as a medicine and more particularly in the treatment of Alzheimer disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention provides pharmaceutical compositions comprising IL-12 muteins, isolated nucleic acids encoding the muteins, vectors, and host cells containing the same, and methods or uses of such compositions for the treatment of a disease or disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A medicament delivery device has an actuation member which is movable relative to a body. The actuation member has a flexible arm comprising an engagement surface. The device has a contoured surface. When the actuation member is in a first position the engagement surface engages the contoured surface. When the actuation member moves to a second position, the flexible arm is deflected radially by the engagement of the engagement surface with the contoured surface. The device further has a blocking member. The blocking member has a proximal portion which engages the flexible arm when the blocking member is in an extended position for preventing the flexible arm from being deflected radially and moving distally. The blocking member is movable relative to the body to disengage the proximal portion from the flexible arm.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A medicament delivery device includes a needle disposed at a distal end of the medicament delivery device, a body for a syringe, and a needle cover axially movable relative to the body between an extended position in which the needle cover covers the needle and a retracted position for dispensing medicament from the medicament delivery device. The needle protruding from the distal end of the needle cover when the needle cover is in the retracted position. The medicament delivery device includes an actuation member configured to be movable from an initial position to an engaged position such that when the actuation member is in its initial position, the needle cover can be axially moved between its retracted position and its extended position, and when the actuation member is in its engaged position, the actuation member engages with the needle cover to hold the needle cover in its retracted position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
Provided herein are artificial microRNA (miRNA) molecules for treating tauopathies. In some embodiments, the miRNA molecules target expression of Tau protein. Further provided herein are expression constructs, vectors (e.g., rAAV), cells, viral particles, and pharmaceutical compositions containing the artificial miRNA molecules. Yet further provided herein are methods and kits related to the use of the miRNA molecules, for example, to treat tauopathies including is Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia with parkinsonism-17, Pick's Disease, argyrophilic grain disease, globular glial tauopathy, chronic traumatic encephalopathy and post-encephalitic parkinsonism.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
79.
MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
Provided herein are artificial microRNA (miRNA) molecules for treating tauopathies. In some embodiments, the miRNA molecules target expression of Tau protein. Further provided herein are expression constructs, vectors (e.g., rAAV), cells, viral particles, and pharmaceutical compositions containing the artificial miRNA molecules. Yet further provided herein are methods and kits related to the use of the miRNA molecules, for example, to treat tauopathies including is Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia with parkinsonism- 17, Pick's Disease, argyrophilic grain disease, globular glial tauopathy, chronic traumatic encephalopathy and post-encephalitic parkinsonism.
A medicament delivery device comprises a housing, a needle, a needle cover, a needle cover biasing member, and a needle cover retaining mechanism. The needle cover is axially movable between an extended position and a retracted position. The needle cover biasing member is configured to bias the needle cover axially in a distal direction towards the extended position. The needle cover retaining mechanism is configured to be moved between a first state, in which the needle cover retaining mechanism is disengaged from the needle cover such that the needle cover is moveable in the distal direction under a force of the needle cover biasing member, and a second state, in which the needle cover retaining mechanism is configured to engage the needle cover and prevent distal movement of the needle cover under the force of the needle cover biasing member, when the needle cover is in the retracted position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A medicament delivery device has a needle for injecting medicament, a body and a needle cover. The needle cover is axially movable relative to a locked position in which the needle cover covers the distal end of the needle. The device has an inner housing with an aperture. A collar is located at least partially within the inner housing and is configured to rotate relative to the inner housing. The collar has one or more arms. A rotational member rotates the collar from a first position to a second position. When the needle cover is in the locked position and the collar is in the second position then the arm extends radially through the aperture and blocks proximal movement of the needle cover away from the locked position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
83.
HUMAN PAH EXPRESSION CASSETTE FOR TREATMENT OF PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY
Provided herein are expression cassettes for expressing a transgene in a liver cell, wherein the transgene encodes a PAH polypeptide. Also provided are methods to treat phenylketonuria (PKU) and/or to reduce levels of phenylalanine in an individual in need thereof. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a PAH polypeptide in an individual in need thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
85.
MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Methods and systems are provided to assess physical movements of a patient based on a video or consecutive images taken of the patient performing a particular physical activity. The assessment can be used for determining a medical disorder or a stage of a medical disorder that the patient suffers.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G06V 40/20 - Movements or behaviour, e.g. gesture recognition
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The present disclosure relates to a medicament delivery device comprising a housing, a needle, a needle cover, a needle cover biasing member, a drive mechanism, and a needle cover extension mechanism. The needle cover is axially movable between an extended position and a retracted position. The needle cover biasing member is configured to bias the needle cover axially in the distal direction towards the extended position. The needle cover extension mechanism comprises a second biasing member and a release element. The second biasing member is configured to bias the needle cover into its extended position post-use of the device. The release element has a first state configured to prevent the second biasing member from biasing the needle cover into the extended position and a second state configured to allow the second biasing member to bias the needle cover into the extended position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat various neurodegenerative disorders. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
A medicament delivery device comprises a housing, a needle, a needle cover, a needle cover biasing member, a skin sensor, a skin sensor biasing member, and a retaining mechanism. The needle cover is axially movable between an extended position and a retracted position. The needle cover biasing member is configured to bias the needle cover towards the extended position. The skin sensor extends from the distal end of the needle cover and is configured to contact an injection site. The skin sensor biasing member is configured to bias the skin sensor from a proximal position to a distal position away from the needle cover. The retaining mechanism is configured to temporarily retain the needle cover in the retracted position and transfer at least a part of the force of the needle cover biasing member to the housing to prevent the needle cover biasing member from moving the needle cover distally.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
92.
METHODS OF TREATING GAUCHER DISEASE AND GBA-PARKINSON’S DISEASE
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat various neurodegenerative disorders. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins.
Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins.
The present disclosure is directed to adapters for mixing vials of drug products, and more specifically to multi-vial adapters for reconstituting lyophilized drug products and/or diluting concentrated drug products. It is an object to address one or more of drawbacks in connection with the drug preparation process, for example, by simplifying the procedure where multiple vials are required to be diluted or reconstituted in a serial manner. As such, the multi-vial adapters described herein simplify the complexity of preparing and handling multiple vials of drug product, which significantly reduces preparation time, addresses dosing-related challenges like weight-based preparation, reduces drug waste issues, and reduces risks associated sterility and contamination, among other benefits.
The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
98.
ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
99.
Collar hold detent mechanism and lock for injection devices
This application relates to an injector device for delivery of a medicament, particularly to an auto-injector device. According to a first aspect of this disclosure, there is described an injection device comprising: an injection device body; a needle shroud retractable into the injection device body comprising a shroud pin; a control spring coupled to the needle shroud and biased to cause the needle shroud to be at least partially extended from the injection device body in an initial position; and a collar rotatable with respect to the injection device body and comprising a cam track engageable with the shroud pin; a hold detent mechanism coupled to the cam track of the collar, wherein the hold detent mechanism is configured to: activate, when the needle shroud is retracted from a first position on the cam track into the injection device body to a hold position on the cam track, by engaging the shroud pin thereby creating a hold detent force opposite a control spring force caused by compression of the control spring during said retraction of needle shroud to said hold position; and deactivate, when the needle shroud is extracted from the hold position on the cam track subsequent to the retraction towards a second position on the cam track, by disengaging the shroud pin thereby releasing the hold detent force and enable the needle shroud to extend from the injection device body to the second position on the cam track; and wherein the hold detent mechanism further comprises a non-return surface configured to, subsequent to the extension of the needle shroud, prevent further retraction of the needle shroud into the injection device body along the cam track towards the hold position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A medicament delivery device for reducing a force required to activate the device includes a needle disposed at a distal end of the device, a needle cover, and a body. The needle cover is axially movable relative to the body between an initial position in which the needle cover covers the needle and an activated position for dispensing a medicament. The needle protrudes from a distal end of the needle cover when the needle cover is in the activated position. The medicament delivery device includes a carrier configured to support a syringe. The carrier is disposed within the needle cover and includes a deformable element configured to change from a first configuration in which the deformable element is engaged with the needle cover to a second configuration in which the deformable element is not engaged with the needle cover.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
